Release Therapeutics Secures CHF 3.3 Million in Seed Funding
Summary
Tragically, this condition is usually diagnosed after symptoms appear, making it too late to treat with available therapies and resulting in most children being unable to survive past the age of five.1Release Tx recently formed a strategic collaboration with the Innovation Unit for Gene and Cell Therapy (GENOV) at the distinguished Paris Brain Institute to assess the impact of the Companys technology in mice presenting symptoms of MLD. The mice were implanted with an analogue of Release Txs Myo-P device and received ARSA enzyme replacement therapy over three months. After three months of treatment, the mice showed reversal of disease progression, suggesting the Companys technology holds great promise in treating symptomatic MLD.2The results were presented by Dr Fran\xe7oise Piguet, Head of GENOV, Paris Brain Institute, at the 20th WORLD Symposium for Lysosomal Storage Disorders (LSD) in February 2024, with the abstract published in a recent special issue of Molecular Genetics and Metabolism.3Release Txs CEO, Thomas Mehrling, said, "The Seed funding raised by Release Tx testifies to the significance of our collaboration with the Paris Brain Institute and our findings towards treating MLD. With the results expected in autumn 2024, we plan to launch a Series A raise in the final quarter of this year to submit an IND application and get our technology into the clinic as soon as possible. The Companys proprietary technology integrates an implantable macroencapsulation device with an immortalised myoblast cell line capable of producing a broad range of proteins for long-term delivery to the CNS.